Boell, Boris and Pluetschow, Annette and Buerkle, Carolin and Atta, Johannes and Pfreundschuh, Michael and Feuring-Buske, Michaela and Vogelhuber, Martin and Soekler, Martin and Eichenauer, Dennis A. and Thielen, Indra and von Tresckow, Bastian and Fuchs, Michael and Engert, Andreas and Borchmann, Peter (2019) Doxorubicin, vinblastine, dacarbazine and lenalidomide for older Hodgkin lymphoma patients: final results of a German Hodgkin Study Group (GHSG) phase-I trial. BRITISH JOURNAL OF HAEMATOLOGY, 185 (1). pp. 42-52. ISSN 0007-1048, 1365-2141
Full text not available from this repository. (Request a copy)Abstract
About 30% of all Hodgkin lymphoma (HL) patients are >= 60 years old. As lenalidomide has promising single agent activity in multiple relapsed HL, we replaced bleomycin in ABVD with lenalidomide in this phase-I trial. Patients aged >= 60 years with early-unfavourable- or advanced-stage HL (Eastern Cooperative Oncology Group performance status <= 2, Cumulative Illness Rating Scale for Geriatrics score 0-7) received 4-8 cycles of AVD (doxorubicin, vinblastine, dacarbazine) and lenalidomide in escalation with overdose control. Dose-limiting toxicities (DLTs) included thromboembolism >= grade 2, severe haematological toxicity, neutropenic fever and prolonged therapy delay. Twenty-five patients with a median age of 68 years were included, 68% had advanced-stage HL. A pre-defined stopping criterion for dose escalation after DLT evaluation of 20/24 patients suggested a recommended phase II dose (RPTD) of 20 mg. DLTs occurred in 10/24 evaluable patients, all treated with >= 20 mg, however, median relative dose intensity was 97% (interquartile range 49-104%). Grade 3 or higher toxicities occurred in all 22 patients at >= 20 mg lenalidomide but no treatment-related deaths occurred. Overall response rate was 80% for all patients (20/25) and 86% (19/22) at >= 20 mg lenalidomide. Three-year estimates for progression-free survival and OS were 69 center dot 7% (95% CI: 50 center dot 3-89 center dot 1%) and 83 center dot 8% (95%-CI: 69 center dot 3-98 center dot 4%), respectively. In conclusion, AVD with lenalidomide 20 mg is feasible and highly effective in older HL patients.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | AGED 60 YEARS; ELDERLY-PATIENTS; COMPREHENSIVE ANALYSIS; BRENTUXIMAB VEDOTIN; RANDOMIZED-TRIAL; BLEOMYCIN; ABVD; CHEMOTHERAPY; CYCLOPHOSPHAMIDE; COMBINATION; Hodgkin lymphoma; older; ABVD; IMID; lenalidomide |
| Divisions: | Medicine > Lehrstuhl für Innere Medizin III (Hämatologie und Internistische Onkologie) |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 20 Apr 2020 06:13 |
| Last Modified: | 20 Apr 2020 06:13 |
| URI: | https://pred.uni-regensburg.de/id/eprint/27292 |
Actions (login required)
 |
View Item |
